Covidien, MedAssets enter contrast agent agreement
Covidien Imaging Solutions has signed a new agreement to supply x-ray contrast imaging agents to customers of MedAssets Supply Chain Systems. The multi-year agreement broadens the scope of Covidien Imaging Solutions products available to MedAssets Supply Chain Systems customers nationwide.
Under the agreement, which became effective Nov. 1, Covidien will provide a range of products used to aid in the diagnosis of disease including x-ray contrast agents, sodium chloride injection, USP 0.9 percent in Ultraject prefilled syringes and MD-Gastroview.
The St. Louis-based company said it will also supply its full portfolio of contrast media injectors to MedAssets’ customers in accordance with a separate agreement signed earlier this year.
Under the agreement, which became effective Nov. 1, Covidien will provide a range of products used to aid in the diagnosis of disease including x-ray contrast agents, sodium chloride injection, USP 0.9 percent in Ultraject prefilled syringes and MD-Gastroview.
The St. Louis-based company said it will also supply its full portfolio of contrast media injectors to MedAssets’ customers in accordance with a separate agreement signed earlier this year.